Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

Fig. 6

h1218-CART19 phase I clinical trial patient characteristics and response. A Swimmers' plot of individual patients with their responses to AT101 over time. Specific NHL subtype and baseline tumor burden is indicated (sum of the product of the diameters (SPD), mm2). See box legends for detail. Note: patients 7 had non-measurable disease involvement of sigmoid colon at time of AT101 infusion and patient 12 did not have a measurable target lesion after bridging therapy. B Waterfall plot depicting the change in tumor burden from baseline to the best response post-treatment for each patient. C Patient 10's PET/CT-scan before AT101 infusion and 1 month after AT101 infusion, showing complete metabolic response. D (Top) Best overall responses across all 12 patients. (Bottom) Best overall response by dose level (DL-1, DL-2, and DL-3). E Progression-free survival of patients treated with AT101. Patients at risk listed below. F Overall survival of patients treated with AT101. Patients at risk listed below

Back to article page

Molecular Cancer

ISSN: 1476-4598